Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Insider filing (Form 144): The filing reports multiple small sales of Common Stock by Robert F. Werner under Rule 144. The disclosed transactions show sales of 7,000 shares on 02/04/2026, 1,693 shares on 02/23/2026, and 246 shares on 03/06/2026. The securities included restricted stock that vested on 05/01/2026 and were listed as compensation-related on the securities to be sold line.
Insider filing (Form 144): The filing reports multiple small sales of Common Stock by Robert F. Werner under Rule 144. The disclosed transactions show sales of 7,000 shares on 02/04/2026, 1,693 shares on 02/23/2026, and 246 shares on 03/06/2026. The securities included restricted stock that vested on 05/01/2026 and were listed as compensation-related on the securities to be sold line.
TWST submitted a Form 144 reporting a planned sale of common stock tied to restricted stock vesting with an effective date of 05/01/2026. The filing lists multiple recent dispositions by Dennis H. Cho in February–March 2026, each showing share counts and gross proceeds.
TWST submitted a Form 144 reporting a planned sale of common stock tied to restricted stock vesting with an effective date of 05/01/2026. The filing lists multiple recent dispositions by Dennis H. Cho in February–March 2026, each showing share counts and gross proceeds.
Twist Bioscience reported strong fiscal second quarter 2026 results, highlighted by record revenue of $110.7 million, up 19% from $92.8 million a year earlier and marking the 13th consecutive quarter of sequential growth. DNA Synthesis and Protein Solutions revenue rose 28% to $53.3 million, while NGS Applications revenue increased 12% to $57.4 million, with both segments growing sequentially.
Gross margin improved to 51.6% from 49.6%, reflecting better profitability on each dollar of sales. Operating expenses were mixed: research and development fell to $19.7 million, but selling, general and administrative costs climbed to $76.1 million. The company also recorded $7.2 million in litigation settlement costs tied to a securities class action.
As a result, net loss widened slightly to $44.0 million, or $0.71 per share, compared with $39.3 million, or $0.66 per share, in the prior-year quarter. Adjusted EBITDA improved modestly to a loss of $13.3 million from $14.8 million. Twist ended March 31, 2026 with $172 million in cash, cash equivalents and short‑term investments and shipped products to approximately 2,583 customers.
Management raised full‑year 2026 revenue guidance to a range of $442 million to $447 million, implying 17–19% growth, and continues to target adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while keeping gross margin above 52% for the year.
Twist Bioscience reported strong fiscal second quarter 2026 results, highlighted by record revenue of $110.7 million, up 19% from $92.8 million a year earlier and marking the 13th consecutive quarter of sequential growth. DNA Synthesis and Protein Solutions revenue rose 28% to $53.3 million, while NGS Applications revenue increased 12% to $57.4 million, with both segments growing sequentially.
Gross margin improved to 51.6% from 49.6%, reflecting better profitability on each dollar of sales. Operating expenses were mixed: research and development fell to $19.7 million, but selling, general and administrative costs climbed to $76.1 million. The company also recorded $7.2 million in litigation settlement costs tied to a securities class action.
As a result, net loss widened slightly to $44.0 million, or $0.71 per share, compared with $39.3 million, or $0.66 per share, in the prior-year quarter. Adjusted EBITDA improved modestly to a loss of $13.3 million from $14.8 million. Twist ended March 31, 2026 with $172 million in cash, cash equivalents and short‑term investments and shipped products to approximately 2,583 customers.
Management raised full‑year 2026 revenue guidance to a range of $442 million to $447 million, implying 17–19% growth, and continues to target adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while keeping gross margin above 52% for the year.
Vanguard Capital Management reported beneficial ownership of 3,101,909 shares of Twist Bioscience Corp common stock, representing 5.05% of the class.
The filing (Schedule 13G) shows sole dispositive power over 3,101,909 shares and sole voting power for 462,865 shares. The report lists the issuer CUSIP 90184D100 and is signed by Ashley Grim on 04/30/2026.
ARK Investment Management LLC and Catherine D. Wood filed an amended Schedule 13G/A reporting beneficial ownership of 6,342,733 shares of Twist Bioscience Corp common stock, representing 10.35% of the class. ARK reports 5,952,949 shares as sole voting power and 6,342,733 as sole dispositive power; Ms. Wood reports 6,049,443 shares as shared voting power and 6,342,733 as shared dispositive power. The filing is signed and dated 04/30/2026.
Twist Bioscience Corp director Melissa A. Starovasnik sold shares in a planned transaction. On April 27, 2026, she completed an open-market sale of 500 shares of Common Stock at $61.83 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating it was scheduled in advance. After this transaction, she continues to hold 25,222 shares directly.
Twist Bioscience Corp’s President and COO Patrick John Finn reported an open-market sale of 2,321 shares of Common Stock at $60.761 per share. According to the footnote, these shares were sold solely to cover tax withholding triggered by vesting of Restricted Stock Units under the company’s equity plans and were not discretionary trades. After this transaction, he directly holds 281,808 shares of Twist Bioscience common stock.
TWST submitted a Rule 144 notice reporting an intended sale of 500 shares of common stock held at Fidelity Brokerage Services LLC, with a listing reference to NASDAQ and a sale-related date of 04/27/2026. The 500 shares trace to restricted stock vesting on 02/07/2024. The filing also records a prior sale of 1,000 shares by Melissa Starovasnik on 04/01/2026 for $51,000.
Twist Bioscience CEO Emily M. Leproust reported option-related trades in Common Stock. She exercised employee stock options to acquire 9,671 shares at an exercise price of $8.82 per share, then sold 9,671 shares in open‑market transactions at prices around $65–66 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions she directly owns 858,887 shares of Common Stock and retains employee stock options, including a grant tied to 64,950 underlying shares with a $67.85 exercise price.
TWST registration statement reports a proposed resale of 2,321 shares of Common Stock tied to restricted stock vesting on 04/22/2026 and lists prior open‑market dispositions by an affiliate, Patrick Finn, totaling multiple transactions in Jan–Feb 2026.
The filing itemizes recent sales by Patrick Finn: 2,390, 2,705, 3,500, 1,750, 68,967, and 4,294 shares on specified dates with corresponding aggregate dollar amounts. This Form 144 is a routine notice of proposed resale by an affiliate under compensation and vesting events.